All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2021-01-24T12:18:21.000Z

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

Featured
Jan 24, 2021
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Alex Herrera, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

Herrera discusses the results from a clinical trial evaluating nivolumab + brentuximab vedotin consolidation therapy for patients with high-risk relapsed/refractory Hodgkin lymphoma after autologous stem cell transplantation. The efficacy and safety results encourage further evaluation of nivolumab + brentuximab vedotin as a posttransplant consolidation therapy.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
46 votes - 78 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox